NanoString Technologies, Inc. is a biotech company offering discovery and translational research solutions.^[1]

This article contains content that is written like an advertisement. (February 2021)

Quick Facts Company type, Traded as ...

NanoString Technologies, Inc

Company type	Public
Traded as	OTC Pink: NSTGQ Nasdaq: NSTG
Industry	Biotechnology
Founded	2003[1]
Founders	Krassen Dimitrov, Amber Ratcliffe, Dwayne Dunaway
Headquarters	South Lake Union, Seattle, Washington , United States
Key people	Brad Gray, CEO
Products	nCounter® Analysis System, GeoMx® Digital Spatial Profiler, CosMx ™ Spatial Molecular Imager, AtoMx ™ Spatial Informatics Portal
Brands	nCounter®, GeoMx® DSP
Revenue	$144.0 million[2] (2021)
Net income	-$80.1 million[2] (2021)
Total equity	$479.5 million[2] (2021)
Number of employees	766[3] (2021)
Website	nanostring.com

Close

NanoString's products include the nCounter Gene Expression System, the GeoMx Digital Spatial Profiler, the CosMx Spatial Molecular Imager, and the AtoMx Spatial Informatics Platform. These four systems enable scientists to envision molecular interactions in three dimensions and see the multiomic expression of genes and proteins in the context of tissue structure. NanoString products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology under the direction of Dr. Leroy Hood.

The original patent forming the basis for the nCounter Analysis System was invented and licensed by The Institute for Systems Biology.^{[citation needed]} The business plan was written by Amber Ratcliffe and Aaron Coe and won seed funding in multiple business plan competitions.^[4] NanoString was spun out of The Institute for Systems Biology and founded as a separate company in 2003 by Krassen Dimitrov, Amber Ratcliffe, and Dwayne Dunaway.^[5]

In 2008, NanoString launched the nCounter Analysis System and began international sales operations with its first multiplexed assays for gene expression analysis.^{[citation needed]}

In 2009, Perry Fell, who had been CEO since 2004, left the company abruptly without official explanation.^[6] Between 2009 and 2010, the company operated with an acting CEO, Wayne Burns.^[7] Brad Gray, a former Genzyme executive, was hired as president and CEO in 2010.^[7]

As of June 2010, the company was not yet profitable.^[7] In an interview, Gray suggested that NanoString would begin to develop clinical diagnostics.^[7] As of July 2012, NanoString began indicating a move towards becoming a public company by hiring several senior staff with public company experience.^[8]

In 2013, the company's IPO raised funding to expand NanoString sales and marketing.^[1] NanoString’s first spatial platform, the GeoMx DSP, was launched in 2019, enabling highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections. The unique combination of high-plex and high-throughput spatial profiling allows researchers to rapidly and quantitatively assess the biological implications of heterogeneity within tissues and has resulted in over 150 peer-reviewed publications as of September 2022.

On February 4, 2024, NanoString Technologies filed for Chapter 11 bankruptcy after laying off 20% of its workforce in October 2023. The company is exploring options to support its restructuring, include a potential sale of itself.^[9]

NanoString's research tools are based on the nCounter Analysis System, which is a modification of the DNA microarray technology.^[10] The nCounter system allows for the simultaneous profiling of hundreds of genes, proteins, miRNAs, or copy number variations with high sensitivity and precision, using molecular barcodes and microscopic imaging in a hybridization reaction.^[11]

To enable spatial transcriptomics and proteomics from one FFPE slide, NanoString introduced the GeoMx Digital Spatial Profiler in 2019. The GeoMx DSP combines whole tissue imaging with gene expression and protein data for single cell resolution in a spatial context.^[12]

NanoString's product pipeline includes the development of the CosMx Spatial Molecular Imager, a single-cell imaging platform that is FFPE-compatible and powered by spatial multiomics. It allows researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment.

In addition, NanoString has developed the AtoMx Spatial Informatics Platform, a cloud-based informatics solution with advanced analytics and global collaboration capabilities, which is expected to launch in 2022.^[13] The AtoMx platform provides a comprehensive, integrated ecosystem for spatial biology insights, enabling global data sharing and collaboration.

Overall, NanoString's continued investment in innovation has led to the development of a range of advanced research tools that offer high sensitivity, precision, and spatial resolution, allowing researchers to gain deep insights into biological systems.